- Trial phase
- Approved
- Time to market
- Already marketed. Braftovi has been commercially available since its initial FDA approval in June 2018.
- Why 3/10
- No scheduled PDUFA date, pivotal readout, or other hard binary catalyst for Braftovi in the next ~12 months. The drug is already approved across three indications and is one of many products in Pfizer's massive portfolio (2026 revenue guidance $62-64B). Without a pending regulatory decision, impactScore cannot exceed 5 per the rubric, and the lack of any dated catalyst plus the drug's small share of Pfizer's overall value places it at 3.
Braftovi has no scheduled PDUFA dates or pivotal readouts in the next 12 months; the next catalyst to watch is whether Pfizer pursues a label expansion for the FOLFIRI chemotherapy backbone based on the positive BREAKWATER Cohort 3 data presented at ASCO 2026. For a company the size of Pfizer, Braftovi is a steady commercial contributor but not a standalone stock-moving catalyst.
Price Chart
Executive Summary
Braftovi (encorafenib) is an oral BRAF kinase inhibitor originally approved by the FDA in June 2018 for BRAF-mutant melanoma. It has since expanded to three approved U.S. indications: melanoma (2018, with binimetinib), metastatic non-small cell lung cancer (October 2023, with binimetinib), and metastatic colorectal cancer (accelerated approval December 2024, converted to full approval February 2026, with cetuximab and chemotherapy). The drug is developed and commercialized by Array BioPharma, a wholly owned subsidiary of Pfizer Inc. (NYSE: PFE). Braftovi is a mature, multi-indication product within Pfizer's massive oncology portfolio and faces no near-term binary regulatory catalysts.
How It Works
Braftovi is a targeted cancer pill that blocks a mutated protein called BRAF, which is found in some cancers and acts like a stuck 'on' switch that tells cancer cells to grow. By turning off this switch, Braftovi slows or stops tumor growth. It is often combined with another drug (binimetinib, sold as Mektovi) that blocks a related protein in the same growth pathway, making the treatment more effective and delaying resistance.
Trial Status
Braftovi is FDA-approved across three indications. The pivotal Phase 3 BREAKWATER trial (NCT04607421) supported the February 2026 full approval for first-line BRAF V600E-mutant metastatic colorectal cancer, showing a 51% reduction in risk of death and a 47% reduction in risk of disease progression with the encorafenib + cetuximab + mFOLFOX6 regimen. Cohort 3 of BREAKWATER, evaluating encorafenib + cetuximab + FOLFIRI, reported positive results at ASCO 2026 showing nearly doubled median progression-free survival versus standard of care. A Phase 2 trial (NCT05217446) of encorafenib + cetuximab + pembrolizumab in first-line mCRC is active but not recruiting (primary completion June 2026). Braftovi is also approved in Japan for BRAF V600-mutated thyroid cancer based on a Phase 2 study.
The Two-Sided Case
Upcoming Catalysts
- Potential FDA supplemental filing for FOLFIRI chemotherapy backbone based on BREAKWATER Cohort 3 data (timing not announced)
- Ongoing Phase 2 trial of encorafenib + cetuximab + pembrolizumab in first-line mCRC (NCT05217446) - results expected
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PFIZER INC 8-K PFE ·Originating report